Psychiatry
Severe Depression
0
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Severe Depression is an early-stage landscape with 0 programs across 4 companies. The most active players are Tasly Pharmaceutical Group Co., Ltd, Eli Lilly, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
11
clinical trials
Completed7 · 64%
Recruiting2 · 18%
Terminated1 · 9%
Not yet recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study
Recruiting·—·Phase 1·NCT07247968·220 enrolled
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00566202·67 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00566202·67 enrolledData sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)